High Purity Rare Ginsenoside Ck Ginsenoside Compound K

【Biological activity】

Ginsenoside C-K is a bacterial metabolite of Ginsenoside Rb1.

Ginsenoside C-K exerts anti-inflammatory effects by inhibiting inducible nitric oxide synthase (iNOS) and COX-2.

In human liver microsomes, Ginsenoside C-K inhibits CYP2C9 and CYP2A6 activity with IC50 values of 32.0 ± 3.6 μ M and 63.6 ± 4.2 μ M, respectively.

【Product Specifications Of Rare Ginsenoside Ck Ginsenoside Compound K】

【In vitro research Of High Purity Rare Ginsenoside Ck Ginsenoside Compound K】

Ginsenoside CK, a bacterial metabolite of G-Rb1, exhibits anti-inflammatory effects mainly by reducing inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX), and pro-inflammatory cytokines.

Ginsenoside CK inhibits the expression of pro-inflammatory cytokines by downregulating the activities of IRAK-1, MAPK, IKK - α, and NF - κ B in LPS treated mouse peritoneal macrophages. Ginsenoside CK also inhibits the expression of iNOS and COX-2 by suppressing NF - κ B signaling in RAW264.7 cells stimulated by LPS.

In bone marrow-derived macrophages (BMDM) and RAW264.7 cells treated with yeast polysaccharides, ginsenoside CK inhibits inflammatory responses by negatively regulating the secretion of pro-inflammatory cytokines, activation of MAPK, and production of ROS. In addition, anti-inflammatory activity of ginsenoside CK was observed in LPS stimulated microglia.

Ginsenoside CK inhibits inflammatory responses by controlling the production of ROS and the activity of MAPKs, NF - κ B, and AP-1.

Ginsenoside CK is the main metabolite of ginsenosides in the gastrointestinal tract, which inhibits NF - κ B signaling in a PXR dependent manner.

Ginsenoside CK promotes the recovery of colitis induced by dextran sulfate sodium (DSS) by inhibiting NF - κ B activation. Ginsenoside CK significantly reduced the upregulation of IL-1 β and iNOS mRNA levels induced by TNF - α, and restored the mRNA levels of PXR and CYP3A4 in LS174T cells.

Ginsenoside CK is one of the intestinal metabolites of 20 (S) - protopanaxadiol derivatives, which has an inhibitory effect on the activity of CYP2C9 in human liver microsomes with an IC50 value of 32.0 ± 3.6 μ M. The inhibitory effect on CYP2A6 activity in human liver microsomes is weaker with an IC50 value of 63.6 ± 4.2 μ M, and the inhibitory effect on CYP2D6 activity in human liver microsomes is weaker with an IC50 value exceeding 100 μ M